Roeser H P, Roberts S J, Kynaston B, Whitaker S V, Hocker G A
Med J Aust. 1977 Dec 17;2(25):821-5. doi: 10.5694/j.1326-5377.1977.tb99332.x.
Combination chemotherapy, which consisted of nitrogen mustard, a vinca alkaloid, procarbazine, and prednisone, was given to 60 patients with disseminated or recurrent Hodgkin's disease. A complete remission of disease was observed in 41 patients, with a median duration of 35+ months. The longest continuing remission was 89 months, and 52% of patients who achieved a complete remission were alive five years from the start of treatment. In contrast, patients who only had a partial remission (11 patients), or failed to respond to therapy (8 patients) fared badly, with a less than 50% survival rate at one year. Response to drug therapy could not be predicted on the basis of sex, age or tumour histology, but patients who had previously received both radiotherapy and chemotherapy had a poor prognosis. Drug toxicity was substantial, but was considered acceptable in view of the clear benefit of treatment to most patients. Further improvement in the outlook of patients with advanced Hodgkin's disease is likely to result from modifications of current drug regimens, possibly combined with non-radical radiotherapy.
对60例播散性或复发性霍奇金病患者给予由氮芥、长春花生物碱、丙卡巴肼和泼尼松组成的联合化疗。41例患者疾病完全缓解，中位缓解持续时间为35+个月。最长持续缓解时间为89个月，41例达到完全缓解的患者中，52%从治疗开始起存活了5年。相比之下，仅部分缓解的患者（11例）或对治疗无反应的患者（8例）预后较差，1年生存率低于50%。无法根据性别、年龄或肿瘤组织学来预测对药物治疗的反应，但既往接受过放疗和化疗的患者预后较差。药物毒性较大，但鉴于对大多数患者治疗有明显益处，毒性被认为是可接受的。晚期霍奇金病患者预后的进一步改善可能源于对当前药物方案的调整，可能联合非根治性放疗。
